Cargando…

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells

Epacadostat is a novel inhibitor of indoleamine-2,3-dioxygenase-1 (IDO1) that suppresses systemic tryptophan catabolism and is currently being evaluated in ongoing clinical trials. We investigated the effects of epacadostat on (a) human dendritic cells (DCs) with respect to maturation and ability to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jochems, Caroline, Fantini, Massimo, Fernando, Romaine I., Kwilas, Anna R., Donahue, Renee N., Lepone, Lauren M., Grenga, Italia, Kim, Young-Seung, Brechbiel, Martin W., Gulley, James L., Madan, Ravi A., Heery, Christopher R., Hodge, James W., Newton, Robert, Schlom, Jeffrey, Tsang, Kwong Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122347/ https://www.ncbi.nlm.nih.gov/pubmed/27192116 http://dx.doi.org/10.18632/oncotarget.9326

Ejemplares similares

Treatment with the IDO inhibitor INCB024360 increased lysis of human tumor cell targets by peptide-specific CTL
por: Jochems, Caroline, et al.
Publicado: (2015)

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
por: Donahue, Renee N., et al.
Publicado: (2017)

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells
por: Lepone, Lauren, et al.
Publicado: (2015)

Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression
por: Grenga, Italia, et al.
Publicado: (2015)

PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients
por: Lepone, Lauren, et al.
Publicado: (2014)

Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses
por: Heery, Christopher R, et al.
Publicado: (2015)

Digital immunohistochemistry analysis of intratumoral immune infiltrates in prostate cancer patients treated with intraprostatic/systemic PSA-TRICOM vaccine
por: Farsaci, Benedetto, et al.
Publicado: (2013)

Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301)
por: Donahue, Renee N, et al.
Publicado: (2014)

Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types
por: Lepone, Lauren M., et al.
Publicado: (2016)

Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival
por: Grenga, Italia, et al.
Publicado: (2013)

The generation and analysis of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic
por: Tsang, Kwong Y, et al.
Publicado: (2015)

A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses
por: Grenga, Italia, et al.
Publicado: (2016)

Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack
por: Grenga, Italia, et al.
Publicado: (2015)

PD-L1 and MHC-I expression in 19 human tumor cell lines and modulation by interferon-gamma treatment
por: Grenga, Italia, et al.
Publicado: (2014)

The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1
por: Panfili, Eleonora, et al.
Publicado: (2023)

Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody
por: Boyerinas, Benjamin, et al.
Publicado: (2014)

The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic
por: Gabitzsch, Elizabeth S., et al.
Publicado: (2015)

Tumor vascular normalization as a strategy to potentiate effectiveness of therapeutic vaccines
por: Farsaci, Benedetto, et al.
Publicado: (2014)

Samarium-153-EDTMP (Quadramet(®)) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial
por: Heery, Christopher R., et al.
Publicado: (2016)

Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer
por: Tucker, Jo A., et al.
Publicado: (2012)

Impact of androgen deprivation therapy on the thymus and the production of naïve T-cells
por: Madan, Ravi A, et al.
Publicado: (2013)

Sphingomyelin-derived nanovesicles for the delivery of the IDO1 inhibitor epacadostat enhance metastatic and post-surgical melanoma immunotherapy
por: Wang, Zhiren, et al.
Publicado: (2023)

Effects of tyrosine kinase inhibitors alone or in combination with vaccine on tumor-infiltrating myeloid cells
por: Donahue, Renee N, et al.
Publicado: (2013)

Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
por: Komiya, Takefumi, et al.
Publicado: (2018)

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology
por: Yue, Eddy W., et al.
Publicado: (2017)

Identification and characterization of agonist epitopes of the MUC1-C oncoprotein
por: Jochems, Caroline, et al.
Publicado: (2013)

Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab
por: Fujii, Rika, et al.
Publicado: (2016)

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
por: Hicks, Kristin C., et al.
Publicado: (2018)

The role of soluble CD40L in immunosuppression
por: Schlom, Jeffrey, et al.
Publicado: (2013)

Impact of age on antigen-specific T lymphocyte response in patients treated with PSA-TRICOM
por: Singh, Harpreet, et al.
Publicado: (2014)

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
por: Lind, Hanne, et al.
Publicado: (2020)

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
por: Gibney, Geoffrey T., et al.
Publicado: (2019)

A poxviral-based cancer vaccine targeting the transcription factor Twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer model
por: Kwilas, Anna R., et al.
Publicado: (2015)

Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
por: Madan, Ravi A, et al.
Publicado: (2012)

Poxviral-based vaccine elicits immunologic responses in prostate cancer patients
por: Madan, Ravi A, et al.
Publicado: (2014)

Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
por: Tsai, Yo-Ting, et al.
Publicado: (2022)

In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer
por: Kwilas, Anna R., et al.
Publicado: (2012)

IL15N72D superagonist/IL15Rα-Fc fusion complex (ALT-803) exhibits anti-metastatic activity in murine breast tumor model
por: Kim, Peter S, et al.
Publicado: (2015)

ABO blood type correlates with survival on prostate cancer vaccine therapy
por: Muthana, Saddam M., et al.
Publicado: (2015)

Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors
por: Luke, Jason J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vggt2rh171272v7kh9c4q2ksu4